Ovid Therapeutics Reports Revenue Decline and Increased Losses in Q2 2026

Ovid Therapeutics Inc. reported a significant decline in revenue for the second quarter of 2026, generating $733,000 compared to $6.3 million in the same period of 2025. This decrease is attributed to a reduction in royalty and licensing revenue, primarily from agreements with NewCo, Marinus, and Immedica. The company also experienced a net loss of $15 million for the quarter, a substantial increase from the $4.7 million loss reported in the prior year. For the first half of 2026, Ovid's total revenue was $733,000, down from $6.4 million in the first half of 2025, with a net loss of $32 million compared to $14.9 million in the previous year.

Operating expenses rose sharply, totaling $16.4 million for the second quarter of 2026, up from $11.3 million in the same quarter of 2025. This increase was driven by higher research and development costs, which reached $10 million, reflecting ongoing clinical activities for lead programs OV329 and OV4071. General and administrative expenses also increased to $6.5 million, influenced by higher professional fees and severance costs. For the first half of 2026, total operating expenses were $34.3 million, compared to $24 million in the same period of 2025.

In terms of strategic developments, Ovid Therapeutics has made significant moves in its operational structure. The company entered into a new agreement in May 2026, transferring its intellectual property rights related to the drug soticlestat to a newly formed entity, NewCo. This agreement is expected to provide Ovid with potential future milestone payments and royalties if the drug is commercialized. Additionally, Ovid raised $56.2 million through a private placement in March 2026 and $75.1 million in October 2025, bolstering its cash reserves to $169.8 million as of June 30, 2026.

The company’s workforce has also expanded, with an increase in employee headcount contributing to higher payroll expenses. As of June 30, 2026, Ovid had a working capital of $113.6 million and an accumulated deficit of $353.7 million. Management believes that the current cash and marketable securities will be sufficient to fund operations for at least the next 12 months. However, Ovid anticipates continued operating losses as it advances its drug candidates through clinical trials and seeks regulatory approvals.

Looking ahead, Ovid Therapeutics expects to incur significant expenses as it continues to develop its pipeline of drug candidates targeting neurological disorders. The company remains focused on securing additional funding through equity offerings, collaborations, and licensing agreements to support its ongoing research and development efforts. The financial outlook remains cautious, with management acknowledging the potential impact of macroeconomic conditions and the need for strategic financial planning to navigate future challenges.